Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
More
China Resources Pharmaceuticals plans to sell an additional 5.88% stake in Tianmai Biotech, with a listing reserve price of 510 million yuan.
CR Pharma Liu Zhiying
On March 16, CR Pharmaceutical (03320) announced that its wholly-owned subsidiary, CR Pharmaceutical Investment Limited (“CR Pharma Investment”), has initiated a potential sale of approximately 5.88% equity interest in Hefei Tianmai Biotechnology Development Co., Ltd. (“Tianmai Biotechnology”). The sale will be publicly listed through the Shanghai United Assets and Equity Exchange, with an initial listing price of approximately 510 million yuan.
CR Pharma stated that the potential sale of shares by CR Pharma Investment and its subsidiaries in Tianmai Biotechnology (as disclosed in the company’s announcement dated February 9, 2026) are independent and unrelated matters. As of the date of this announcement, CR Pharma Investment and its subsidiaries hold about 23.75% of Tianmai Biotechnology.
According to records, on February 9, CR Pharma announced that CR Pharma Investment had initiated a potential sale of approximately 17.87% of its shares in Tianmai Biotechnology, which will be publicly listed through the Shanghai United Assets and Equity Exchange, with a listing price of about 1.42 billion yuan. At that time, CR Pharma Investment and its subsidiaries held less than 30% of Tianmai Biotechnology.
CR Pharma was established in 2007, with business covering the manufacturing and commercial distribution of pharmaceuticals, health products, and medical devices. Its subsidiaries include China Resources Pharmaceutical Commercial Group Co., Ltd., China Resources Sanjiu Medical & Pharmaceutical Co., Ltd., China Resources Shuanghe Pharmaceutical Co., Ltd., China Resources Jiangzhong Pharmaceutical Group Co., Ltd., and Dong’e E Jiao Co., Ltd.
In the first half of 2025, CR Pharma achieved operating revenue of 131.867 billion yuan, a year-on-year increase of 2.54%; net profit attributable to the parent company was 2.077 billion yuan, a decrease of 20.25% year-on-year.
Related company: China Resources Pharmaceutical HK 03320